When was Beyond Air founded?

Beyond Air was founded in 2011 and raised its 1st funding round 10 years after it was founded.

Where is Beyond Air located?

Beyond Air is headquartered in Garden City, United States.

How many employees does Beyond Air have?

As of Aug 31, 2026, the latest employee count at Beyond Air is 69.

Is Beyond Air a funded company?

Beyond Air is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Feb 16, 2021.

When was the latest funding round of Beyond Air?

Beyond Air's latest funding was a $***** Post IPO round on Sep 26, 2024, with participation from 0 investor. Its primary sector is Pulmonology. In United States, the Pulmonology sector has seen $990M in funding in 2026 to date.

What is the annual revenue of Beyond Air?

Annual revenue of Beyond Air is between $1M and $10M as on Mar 31, 2026

Where does Beyond Air rank among its competitors?

Beyond Air ranks 4th amongst 111 active competitors, of which 27 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Nebu~Flow, which secured $2.69M in Jun, 2026.

Who are the top competitors of Beyond Air?

Beyond Air's top competitors include MannKind Corp, Impel NeuroPharma and Alexza. Among them, Nebu~Flow secured the most recent funding round in June, 2026.

Beyond Air - 2026 Company Profile, Team, Funding, Competitors & Financials

Beyond Air is a public company based in Garden City (United States), founded in 2011 by Amir Avniel. It operates as a Developer of therapeutics for multiple diseases. Beyond Air has raised an undisclosed amount in funding. The company has 111 active competitors, including 27 funded and 20 that have exited. Its top competitors include companies like MannKind Corp, Impel NeuroPharma and Alexza.

Company Details

Developer of therapeutics for multiple diseases. The company focusing on developing pipeline of products that address respiratory therapeutic areas, cancer, and autism spectrum disorder.

Website: www.beyondair.net/
Social
Email ID: *****@beyondair.net
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

Garden City, United States

Stage

Public

Latest Funding Round

Post IPO, Sep 26, 2024, $*****

Investors

Collage Venture Partners & 1 more

Ranked

4^th among 111 active competitors

Annual Revenue

$1M - $10M as on Mar 31, 2026

Employee Count

69 as on Aug 31, 2026

Similar Companies

MannKind Corp & 128 more

Exit Details

Public

View Beyond Air's full profile

Beyond Air is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BEYOND AIR, INC. CIN: 1641631 , United States, Deadpooled	Apr 27, 2015	$1M - $10M (As on Mar 31, 2026)	-	-
Beyond Air, Inc CIN: 473812456 , United States, Active	Dec 31, 2010	-	-	-

Beyond Air got listed on Sep 22, 2017.

Click here to take a look at Beyond Air's IPO in detail

Beyond Air has raised funding over 4 rounds. Its first funding round was on Feb 16, 2021. Beyond Air has 2 institutional investors.

Here is the list of recent funding rounds of Beyond Air:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 26, 2024	6190370	Post IPO	2605390	3840840	1707490	4882823
Jun 24, 2024	7366089	Post IPO	4039094	5366780	3716986	6264680
Jun 28, 2023	4838538	Post IPO	5227765	5821557	9773653	8396271

Access funding benchmarks and valuations. Sign up today!

View details of Beyond Air's funding rounds and investors

The founders of Beyond Air is Amir Avniel. Steve Lisi is the CEO of Beyond Air.

Here are the details of Beyond Air's key team members:

Amir Avniel: Co-Founder & COO of Beyond Air.
Steve Lisi: CEO of Beyond Air.
Contact Info: 1 email address

View details of Beyond Air's Founder profiles and Board Members

Beyond Air's employee count trend

Beyond Air has 69 employees as of Aug 26. Here is Beyond Air's employee count trend over the years:

Uncover Beyond Air's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Beyond Air include MannKind Corp, Impel NeuroPharma and Alexza. Here is the list of Top 10 competitors of Beyond Air, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
2nd	Impel NeuroPharma 2008, Seattle (United States), Public	Developer of an intranasal drug delivery technology for CNS diseases	$120M	VenBio, Norwest & 7 others	63/100
3rd	Alexza 2000, Mountain View (United States), Public	Developer of products for the treatment of acute and intermittent conditions	$97M	Versant Ventures, Frazier Healthcare Partners ... & 16 others	61/100
4th	Beyond Air 2011, Garden City (United States), Public	Developer of therapeutics for multiple diseases	-	Collage Venture Partners, Cystic Fibrosis Foundation ... Read more	57/100
5th	Qnovia 2018, Richmond (United States), Series B	Developer of inhaled drug delivery devices to deliver a broad range of pharmaceuticals	$50M	Blue Ledge Capital, Evolution VC Partners ... & 4 others	55/100
6th	Iconovo 2013, Lund (Sweden), Public	Develops inhalation devices	$3.56M	Smile Incubator, Eiffel Investment Group & 2 others	55/100
7th	OptiNose 2000, Morrisville (United States), Acquired	Developer of smart devices for nasal drug delivery	$120M	Avista Capital Partners, Fidelity Investments ... & 6 others	53/100
8th	NeOnc Technologies 2008, Los Angeles (United States), Public	Developer of drug delivery methods for pharma-based therapeutics	$18.7M	NIH, S3 Capital	52/100
9th	Nebu~Flow 2019, Glasgow (United Kingdom), Series A	Developer of aerosol delivery platform technology	$7.97M	Foresight Group, SCVC & 8 others	51/100
10th	Neurelis 2007, Encinitas (United States), Series D	Therapeutics for CNS disorders	$221M	HBM Healthcare Investments, LYZZ Capital & 4 others	51/100